Vaccine Tracking Data—The Next Big Alt Dataset
Investment firms and vendors are searching for signals in healthcare and pharmaceutical data in a bid to get a leg up on a Covid-19 vaccine.
One year ago, no one foresaw the coronavirus pandemic and the havoc it would wreak on every aspect of life and work. As fear and anxiety have spread across the globe, it’s becoming increasingly clear that the only way back to “normal” is the development of a drug that combats the Covid-19 virus.
While ordinary people anxiously await a vaccine, the market is transfixed by the idea of a treatment for this highly contagious disease. Investors are keen to bet on which companies will be successful
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: https://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Data Management
CME, LSEG align on market data licensing in GenAI era
The two major exchanges say they are licensing the use case—not the technology.
Data infrastructure must keep pace with pension funds’ private market ambitions
As private markets grow in the UK, Keith Viverito says the infrastructure that underpins the sector needs to be improved, or these initiatives will fail.
AI enthusiasts are running before they can walk
The IMD Wrap: As firms race to implement generative and agentic AI, having solid data foundations is crucial, but Wei-Shen wonders how many have put those foundations in.
Jump Trading spinoff Pyth enters institutional market data
The data oracle has introduced Pyth Pro as it seeks to compete with the traditional players in market data more directly.
50% of firms are using AI or ML to spot data quality issues
How does your firm stack up?
FCA files to lift UK bond tape suspension, says legal claims ‘without merit’
After losing the bid for the UK’s bond CT, Ediphy sued the UK regulator, halting the tape’s implementation. Now, the FCA is asking the UK’s High Court to end the suspension and allow it to fight Ediphy’s claims in parallel.
Waters Wavelength Ep. 339: Northern Trust Asset Management’s Jan Rohof
This week, Jan Rohof from Northern Trust Asset Management joins to discuss how asset managers and quants get more context from data.
Tokenization & Private Markets: Where mixed data finds a needed partner?
Waters Wrap: Reading the tea leaves, Anthony predicts BlackRock’s Preqin deal, Securitize’s IPO, and numerous public comments from industry leaders are just the tip of the iceberg.
